Stoke Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
STOK$27.71+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated balance sheets
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $84,220 | $127,983 |
| Marketable securities - short term | 200,450 | 88,916 |
| Accounts receivable | 5,936 | 1,668 |
| Prepaid expenses | 8,736 | 11,117 |
| Other current assets | 3,895 | 2,297 |
| Restricted cash - short term | 494 | 75 |
| Interest receivable | 1,969 | 700 |
| Total current assets | $305,700 | $232,756 |
| Restricted cash - long term | 227 | 721 |
| Operating lease right-of-use assets | 3,101 | 4,345 |
| Marketable securities - long term | 106,260 | 29,824 |
| Property and equipment, net | 3,146 | 3,909 |
| Total assets | $418,434 | $271,555 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,939 | $2,498 |
| Accrued and other current liabilities | 41,035 | 18,567 |
| Deferred revenue - current portion | 11,901 | 18,991 |
| Total current liabilities | $57,875 | $40,056 |
| Deferred revenue - net of current portion | 6,961 | — |
| Other long term liabilities | 1,141 | 2,478 |
| Total long term liabilities | $8,102 | $2,478 |
| Total liabilities | $65,977 | $42,534 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 58,921,999 and 54,032,826 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 5 | 5 |
| Additional paid-in capital | 849,624 | 719,997 |
| Accumulated other comprehensive income (loss) | 543 | (151) |
| Accumulated deficit | (497,715) | (490,830) |
| Total stockholders’ equity | $352,457 | $229,021 |
| Total liabilities and stockholders’ equity | $418,434 | $271,555 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.